相关实验视频

Updated: Feb 28, 2026

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

在接受索福斯布维尔/韦尔帕塔斯维尔治疗的肝炎C病毒感染患者的第四周持续病毒反应的预测值

Gia Landry^1,2, Mark Sulkowski³, Jordan J Feld⁴

¹Lane Regional Medical Center, Zachary, LA 70791, USA.

|February 27, 2026

概括

在4周的持续病毒学反应 (SVR4) 准确地预测了在使用索福斯布维尔/韦尔帕塔斯维尔时的C型肝炎病毒 (HCV) 治愈. 将治愈确认转移到SVR4可以改善患者的随访并减少护理损失.

科学领域:

肝病学肝病学是一种肝病学.
病毒学病毒学
临床医学临床医学

背景情况:

型肝炎病毒 (HCV) 直接作用的抗病毒疗法提供高治愈率.
在治疗后确认持续的病毒学反应 (SVR) 对HCV消除至关重要.
目前的SVR确认通常是在治疗后12周 (SVR12),这对患者的坚持提出了挑战.

研究的目的:

为了评估持续的病毒学反应在4周 (SVR4) 作为预测SVR12在患者治疗索福斯布维尔/韦尔帕塔维尔 (SOF/VEL).
在临床试验和现实环境中评估SVR4和SVR12之间的一致性.
为了确定使用SVR4用于早期HCV治愈确认的可行性.

主要方法:

从第三阶段的ASTRAL (1, 2, 3) 计划中对患者进行了回顾性分析.
来自路易斯安那州卫生部索赔数据库的真实世界队列的分析.
一致性分析比较SVR4和SVR12结果.

主要成果:

在ASTRAL研究 (n=1015) 和现实世界队列 (n=509) 中观察到SVR4和SVR12之间的高度一致性.
在ASTRAL中,3/1005个SVR4实现者失败了SVR12;所有10/10个非SVR4实现者都失败了SVR12.
在现实世界队列中,7/479名SVR4成绩者失败SVR12;17/30名非SVR4成绩者失败SVR12.

结论:

在接受SOF/VEL治疗HCV感染的患者中,SVR4是SVR12的可靠预测剂.
使用SVR4来确认治愈可能会简化护理并减少患者对随访的损失.
早些时候确定SVR可以加强HCV消除工作.

关键词:

慢性型肝炎 C 的病例.协和书的协和书是指一个协和书.直接作用的抗病毒药物.型肝炎C型肝炎的发生对后续行动的损失.边缘化的人口边缘化的人口.持续的病毒学反应.在治疗后4周持续的病毒学反应.

更多相关视频

A Protocol for Analyzing Hepatitis C Virus Replication

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

相关概念视频

Sensitivity, Specificity, and Predicted Value

Sensitivity, Specificity, and Predicted Value

In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...

Drug Product Performance: In Vitro–In Vivo Correlation

Drug Product Performance: In Vitro–In Vivo Correlation

In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...